How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Zacks
More News
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
Zacks
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Zacks
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $61.4, denoting a +1.05% move from the preceding trading day.
Zacks
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Zacks
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.